Lifeng Li
12 Papers
Lifeng Li is an academic researcher. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients.
Yongliang Zhang,Yu Yao,Yaping Xu,Lifeng Li,Yan Gong,Kai Zhang,Meng Zhang,Yanfang Guan,Lianpeng Chang,Xuefeng Xia,Lin Li,S. Jia,Qiang Zeng +12 more
TL;DR: The authors analysed more than 10,000 patients using a targeted sequencing panel and report on the frequencies of the mutations that they found, which may be helpful for identifying therapeutic targets and combined treatment strategies.
PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS
Jihao Zhou,Min Zuo,Lifeng Li,Fafen Li,Peng Ke,Ya-Dong Zhou,Yaping Xu,Xuan Gao,Yanfang Guan,Xuefeng Xia,Xin Yi,Xinyou Zhang,Yuhua Huang +12 more
TL;DR: A new molecular classification was developed to divide CNS DLBCL into CDP and non-CDP groups based on CD79B and PIM1 mutational status, which revealed the subcloning heterogeneity between the groups.
Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
Gang Xiao,Lifeng Li,Guilong Tanzhu,Zhiyuan Liu,Xuan Gao,Xingsheng Wan,Desheng Xiao,Liu Chen,Xuefeng Xia,Rongrong Zhou +9 more
TL;DR: In this paper , the authors found that lung adenocarcinomas (LUAD) with EGFR/ALK-positive BMs exhibited an immunosuppressive microenvironment, manifested as inhibition of immune-related pathways; low expression of immune checkpoint; decreased infiltration of CD8+T cells and cytotoxic lymphocyte; increased proportion of suppressive M2 macrophages.
Comprehensive Comparative Molecular Characterization of Young and Old Lung Cancer Patients
Mingming Hu,Jinjing Tan,Zhentian Liu,Lifeng Li,Dan Zhao,Baolan Li,Xuan Gao,Nanying Che,Hongmei Zhang +8 more
TL;DR: Although young lung patients with NSCLC had better outcomes, there were still adverse factors of them, suggesting that the young group still needs more caution for treatment choice and monitoring after the treatment to further improve the prognosis.
CD8+ T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer types
Xinlong Zheng,Kan Jiang,Weijin Xiao,Dongqiang Zeng,Wenying Peng,Jing Bai,Xiaohui Chen,Pansong Li,Longfeng Zhang,Xiaobing Zheng,Qian Miao,Haibo Wang,Shiwen Wu,Yiquan Xu,Haipeng Xu,Chao Li,Lifeng Li,Xuan Gao,Suya Zheng,Junhui Li,Deqiang Wang,Zhi Rui Zhou,Xuefeng Xia,Shanshan Yang,Yujing Li,Zhaolei Cui,Qiuyu Zhang,Ling Chen,Xiandong Lin,Gen Lin +29 more
TL;DR: In this paper , the CD8+ T cell/CAF ratio (CFR) association with survival was investigated in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) lung cancer cohorts.